Table 1 General characteristics and outcomes of patients receiving desmopressin and those not receiving desmopressin
Variable | Total (n = 262) | No desmopressin (n = 223) | Desmopressin (n = 39) | p |
|---|---|---|---|---|
Age, years | 46 ± 19 | 48 ± 19 | 35 ± 13 | < 0.001 |
Weight, kg | 76 ± 14 | 77 ± 14 | 76 ± 10 | 0.99 |
Male, n (%) | 202 (77) | 168 (75) | 34 (87) | 0.10 |
GCS prior to sedation | 6 [3–8] | 6 [4–8] | 3 [3–6] | 0.01 |
Fixed pupils at admission | 87 (33) | 66 (30) | 21 (62) | 0.003 |
Marshall score | 3 [2–5] | 3 [2–5] | 5 [3–5] | 0.09 |
ISS | 30 [25–42] | 30 [25–42] | 31 [25–44] | 0.58 |
APACHE II | 20 [15–26] | 19 [15–25] | 23 [15–37] | 0.14 |
Neurosurgery (clot evacuation), n (%) | 94 (36) | 76 (34) | 18 (46) | 0.15 |
EVD, n (%) | 84 (32) | 69 (31) | 15 (38) | 0.35 |
Extended IMPACT predicted 6 month-mortality, % | 25 [14–40] | 25 [13–39] | 28 [17–44] | 0.42 |
Osmotherapy within 7 days, n (%) | 140 (53) | 125 (56) | 28 (72) | 0.066 |
Hospital Mortality, n (%) | 63 (24) | 57 (26) | 16 (41) | 0.04 |
Hospital stay, days | 20 [10–31] | 20 [12–31] | 19 [6–31] | 0.14 |
ICU stay, days | 14 [8–21] | 14 [9–20] | 17 [5–25] | 0.74 |